Clinicopathologic correlation of cancer stem cell markers CD44, CD24, VEGF and HIF-1α in ductal carcinoma in situ and invasive ductal carcinoma of breast: An immunohistochemistry-based pilot study

Pathology Research and Practice

Volumn 207, Issue 8, 2011, Pages 505-513

  Wang, Zhen ^a   Shi, Qin ^b   Wang, Zemin ^c   Gu, Yongping ^d   Shen, Yueping ^d   Sun, Maoming ^d   Deng, Min ^d   Zhang, Hua ^d   Fang, Junchu ^a   Zhang, Shuying ^a   Xie, Fang ^d  

^a THE SECOND AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^c LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d SOOCHOW UNIVERSITY   (China)

Author keywords

Breast; Cancer stem cells; Ductal carcinoma in situ; HIF 1 ; Invasive ductal carcinoma; VEGF

Indexed keywords

CD24 ANTIGEN; HERMES ANTIGEN; HYPOXIA INDUCIBLE FACTOR 1BETA; VASCULOTROPIN;

ARTICLE; BREAST; BREAST CARCINOGENESIS; BREAST CARCINOMA; CANCER GRADING; CANCER GROWTH; CANCER STAGING; CANCER STEM CELL; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CORRELATIONAL STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; INVASIVE CARCINOMA; MAJOR CLINICAL STUDY; PILOT STUDY; PROTEIN EXPRESSION; PROTEIN LOCALIZATION;

ADULT; AGED; ANTIGENS, CD24; ANTIGENS, CD44; BREAST NEOPLASMS; CARCINOMA IN SITU; CARCINOMA, DUCTAL, BREAST; FEMALE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASTIC STEM CELLS; PILOT PROJECTS; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 80051784212     PISSN: 03440338     EISSN: 16180631     Source Type: Journal    
DOI: 10.1016/j.prp.2011.06.009     Document Type: Article

References (36)

1. Abraham B.K., Fritz P., McClellan M., Hauptvogel P., Athelogou M., Brauch H. Prevalence of CD44+/CD24-/low cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis. Clin. Cancer Res. 2005, 11:1154-1159.
2. Al-Hajj M., Wicha M.S., Benito-Hernandez A., Morrison S.J., Clarke M.F. Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:3983-3988.
3. Bircan S., Kapucuoglu N., Baspinar S., Inan G., Candir O. CD24 expression in ductal carcinoma in situ and invasive ductal carcinoma of breast: an immunohistochemistry-based pilot study. Pathol. Res. Pract. 2006, 202:569-576.
4. Baumann P., Cremers N., Kroese F., Orend G., Chiquet-Ehrismann R., Uede T., et al. CD24 expression causes the acquisition of multiple cellular properties associated with tumor growth and metastasis. Cancer Res. 2005, 65:10783-10793.
5. Büchler P., Reber H.A., Büchler M., Shrinkante S., Büchler M.W., Friess H., et al. Hypoxia-inducible factor 1 regulates vascular endothelial growth factor expression in human pancreatic cancer. Pancreas 2003, 26:56-64.
6. Chang C.C. Recent translational research: stem cells as the roots of breast cancer. Breast Cancer Res. 2006, 8:103-105.
7. Collins A.T., Berry P.A., Hyde C., Stower M.J., Maitland N.J. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res. 2005, 65:10946-10951.
8. Costa F.F., Le Blanc K., Brodin B. Concise review: cancer/testis antigens, stem cells, and cancer. Stem Cells 2007, 25:707-711.
9. Dave B., Chang J. Treatment resistance in stem cells and breast cancer. J. Mammary Gland Biol. Neoplasia 2009, 14:79-82.
10. Detwiller K.Y., Fernando N.T., Segal N.H., Ryeom S.W., D'Amore P.A., Yoon S.S. Analysis of hypoxia-related gene expression in sarcomas and effect of hypoxia on RNA interference of vascular endothelial cell growth factor A. Cancer Res. 2005, 65:5881-5889.
11. Fillmore C.M., Kuperwasser C. Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. Breast Cancer Res. 2008, 10:R25.
12. Galanis A., Pappa A., Giannakakis A., Lanitis E., Dangaj D., Sandaltzopoulos R. Reactive oxygen species and HIF-1 signalling in cancer. Cancer Lett. 2008, 266:12-20.
13. Generali D., Buffa F.M., Berruti A., Brizzi M.P., Campo L., Bonardi S., et al. Phosphorylated ERalpha, HIF-1alpha, and MAPK signaling as predictors of primary endocrine treatment response and resistance in patients with breast cancer. J. Clin. Oncol. 2009, 27:227-234.
14. Ivan M., Kondo K., Yang H., Kim W., Valiando J., Ohh M., et al. HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science 2001, 292:464-468.
15. Knowles H.J., Athanasou N.A. Hypoxia-inducible factor is expressed in giant cell tumour of bone and mediates paracrine effects of hypoxia on monocyte-osteoclast differentiation via induction of VEGF. J. Pathol. 2008, 215:56-66.
16. Kokko L.L., Hurme S., Maula S.M., Alanen K., Grénman R., Kinnunen I., et al. Significance of site-specific prognosis of cancer stem cell marker CD44 in head and neck squamous-cell carcinoma. Oral Oncol. 2011, 47:510-516.
17. Lebeau A., Turzynski A., Braun S., Behrhof W., Fleige B., Schmitt W.D., et al. Reliability of human epidermal growth factor receptor 2 immunohistochemistry in breast core needle biopsies. J. Clin. Oncol. 2010, 28:3264-3270.
18. Murphy J.F., Lennon F., Steele C., Kelleher D., Fitzgerald D., Long A.C. Engagement of CD44 modulates cyclooxygenase induction, VEGF generation, and proliferation in human vascular endothelial cells. FASEB J. 2005, 19:446-448.
19. O'Brien C.A., Pollett A., Gallinger S., Dick J.E. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007, 445:106-110.
20. Oku T., Tjuvajev J.G., Miyagawa T., Sasajima T., Joshi A., Joshi R., et al. Tumor growth modulation by sense and antisense vascular endothelial growth factor gene expression: effects on angiogenesis, vascular permeability, blood volume, blood flow, fluorodeoxyglucose uptake, and proliferation of human melanoma intracerebral xenografts. Cancer Res. 1998, 58:4185-4192.
21. Oliveira L.R., Jeffrey S.S., Ribeiro-Silva A. Stem cells in human breast cancer. Histol. Histopathol. 2010, 25:371-385.
22. Ponti D., Zaffaroni N., Capelli C., Daidone M.G. Breast cancer stem cells: an overview. Eur. J. Cancer 2006, 42:1219-1224.
23. Rankin E.B., Giaccia A.J. The role of hypoxia-inducible factors in tumorigenesis. Cell Death Differ. 2008, 15:678-685.
24. Reya T., Morrison S.J., Clarke M.F., Weissman I.L. Stem cells, cancer, and cancer stem cells. Nature 2001, 414:105-111.
25. Ricci-Vitiani L., Lombardi D.G., Pilozzi E., Biffoni M., Todaro M., Peschle C., et al. Identification and expansion of human colon-cancer-initiating cells. Nature 2007, 445:111-115.
26. Sheridan C., Kishimoto H., Fuchs R.K., Mehrotra S., Bhat-Nakshatri P., Turner C.H., et al. CD44+/CD24- breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis. Breast Cancer Res. 2006, 8:R59.
27. Singh S.K., Hawkins C., Clarke I.D., Squire J.A., Bayani J., Hide T., et al. Identification of human brain tumour initiating cells. Nature 2004, 432:396-401.
28. Surowiak P., Materna V., Györffy B., Matkowski R., Wojnar A., Maciejczyk A., et al. Multivariate analysis of oestrogen receptor alpha, pS2, metallothionein and CD24 expression in invasive breast cancers. Br. J. Cancer 2006, 95:339-346.
29. Tavassoéli F.A., Devilee P. Pathology and Genetics Tumours of the Breast and Female Genital Organs [M] 2003, IARC Press, Lyon, p. 10.
30. Teicher B.A. Hypoxia and drug resistance. Cancer Metastasis Rev. 1994, 13:139-168.
31. Wicha M.S. Identification of murine mammary stem cells: implications for studies of mammary development and carcinogenesis. Breast Cancer Res. 2006, 8:109-111.
32. Xie F., Shi Q., Wang Q., Ge Y., Chen Y., Zuo J., et al. CD40 is a regulator for vascular endothelial growth factor in the tumor microenvironment of glioma. J. Neuroimmunol. 2010, 222:62-69.
33. Xie F., Wang Q., Chen Y., Gu Y., Mao H., Zeng W., et al. Costimulatory molecule OX40/OX40L expression in ductal carcinoma in situ and invasive ductal carcinoma of breast: an immunohistochemistry-based pilot study. Pathol. Res. Pract. 2010, 206:735-739.
34. Yang J., Tang T., Li F., Liu J., Tan Z., Zheng W., et al. Experimental study of the effects of marrow mesenchymal stem cells transfected with hypoxia-inducible factor-1alpha gene. J. Biomed. Biotechnol. 2009, 2009:128627-128637.
35. Yu K.D., Liu G.Y., Di G.H., Wu J., Lu J.S., Shen K.W., et al. Progesterone receptor status provides predictive value for adjuvant endocrine therapy in older estrogen receptor-positive breast cancer patients. Breast 2007, 16:307-315.
36. Yoon S.Y., Lee H.R., Park Y., Kim J.H., Kim S.Y., Yoon S.R., et al. Thymosin β4 expression correlates with lymph node metastasis through hypoxia inducible factor-α induction in breast cancer. Oncol. Rep. 2011, 25:23-31.